加载中...
长期深耕跨境科创，见过太多因信息差、文化壁垒、决策失误止步的合作和投资项目，于是决定用播客记录。
访谈一线操盘者、投资人、创始人，还原跨境交易最真实的成败经验，给出海创业者、跨境投资人一点可落地的参考。 纯干货无空谈。8 月18日上线
May I share with you all my new podcast about cross - boarder deal making? Interviewing founders, investors and corp innovators who actually close deal between China and the world
. 🎙️InnoBridge｜S01E01 is alive now!
Guest：Mati Gill｜Founder & CEO, AION Labs
嘉宾：AION Labs创始人兼CEO Mati Gill
Under strict antitrust rules, brought Pfizer, AstraZeneca, Merck & Teva, four pharma competitors, to jointly build an AI‑pharma venture studio.
严守反垄断纪律，促成辉瑞、阿斯利康、默克、Teva四大药企对手共建AI制药创投工作室。
📝Key topics 核心话题
▫️AION Labs偏好的创始人画像｜Founder criteria at AION Labs
▫️反垄断框架下，说服竞品合作｜Convincing rivals to collaborate under antitrust constraints
▫️百万美元项目成功退出 & 关停项目惨痛复盘｜$1M‑funded exit & costly lessons from shut‑down project
▫️Teva重启中国市场实战经验｜Teva’s China re‑entry strategy
▫️初创企业市场切入策略｜Startup go‑to‑market
▫️药企中国机遇与以色列创新｜Pharma’s China gold rush & Israeli innovation
▫️AI制药未来五年行业变革｜Future of AI pharma in 5 years
🇨🇳🇮🇱Sino‑Israeli pharma innovation
📻Full episode：YouTube / Spotify / Apple / Xiaohongshu / Bilibili — search "InnoBridge" to watch.
🔗Links｜收听链接
Spotify：https://open.spotify.com/episode/5n8bSRXtEqWPZw6AWS8owP?si=iYX_CQA_S‑aS7h_Tqs06pg
Apple Podcast：https://podcasts.apple.com/il/podcast/four‑rival‑pharma‑one‑venture‑studio‑mati‑gill‑on‑building/id6802754511?i=1000784141147
Bilibili：https://b23.tv/dCH74c0
获取最新资讯与动态：
Copyright © 2026 RADHOST PTE. LTD. (UEN: 202450723N). All Rights Reserved.
